Displaying 76–100 of 10929 results for

Sort By Relevance Sort By Date
1... 2 3 4 5 6 ...438

Trump suggests executive order on drug prices, but is unclear on details

(News)

President Trump mentioned that the White House was writing an executive order to require pharma companies to offer the U.S. government lower prices — but did not elaborate on details.

Biosimilars are coming to LATAM

(Article)

There is a flourishing biosimilar industry in Latin America, with its own research, development, production and commercialization capacity.

Amicus inks gene therapy deals with Thermo Fisher and Catalent

(News)

Amicus Therapeutics has found CDMO partners to manufacture its gene therapies.

Joint GSK and Pfizer venture wins conditional approval in South Africa

(News)

According to the Competition Commission in South Africa, the deal was not likely to reduce competition.

Novartis buys Takeda's eye med Xiidra for $3.4 billion

(News)

The drugs is the only prescription treatment approved by the FDA for both signs and symptoms of dry eye disease, with a mechanism of action that targets inflammation.

The top 5 new drugs bound for blockbuster status

(Article)

A wave of incoming anti-inflammatories and gene therapies that could make it big

Will product drift cause a rift?

(Article)

It’s important to consider how product drift will impact biosimilars

Lonza scoops up Novartis bottling plant

(News)

Lonza has been looking for a way to more efficiently fill-and-finish its injectable drugs and has found a solution by buying a Novartis bottling plant.

Pfizer completes Therachon buy

(News)

Pfizer has announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company, Therachon Holding.

UBiome startup execs quit amid FBI probe

(News)

UBiome’s interim CEO, John Rakow, who took over in the wake of a Federal Bureau of Investigation's search of the startup’s San Francisco offices in late April, has left the company.

Enhancing the Paragraph IV Patent Certifications List database

(Article)

FDA looks to improve transparency and predictability for generic drug applicants.

Perfecting CAPA

(Article)

Quality & Compliance: “Flawless” may not exist on the plant floor, but reviewing your quality process can save money and lives.

European regulators won't back Amgen/UCB drug

(News)

Amgen and Belgian partners at UCB announced that the EMA has adopted a negative opinion on Evenity, for the treatment of osteoporosis in men and in postmenopausal women at increased risk of fracture.

Retrofitting batch with single-use

(Article)

Automation & Control: Single-use technologies offer multiple benefits for those who can overcome instrumentation challenges.

eBook: Generic Drugs 2019

(Whitepaper)

Biosimilar commercialization challenges, real-world tips for updating aging facilities and a deep dive into interchangeability guidance.

CDMO trends: Drug development and industry consolidation

(Article)

How those in the outsourcing sector can be more prepared to meet shifting customer demands as the industry continues to evolve.

Novartis gets tangled in chemical weapons controversy

(News)

Critics have taken aim at Novartis for its ties to a company that bought APIs in Syria that could have been used to make chemical weapons.

New approval for Dupixent could help propel it to blockbuster status

(News)

The FDA has given Dupixent the go-ahead as a treatment for nasal polyps.

FDA DSCSA Pilot Project Program

(Article)

A Q&A about the FDA DSCSA Pilot Program Pilot

AbbVie buys Allergan for $63 billion

(News)

The newly combined company will be led by Abbvie chairman and CEO Richard Gonzalez.

Akorn hit with yet another FDA warning letter

(News)

The warning letter is the result of an inspection of the company’s Somerset, New Jersey-based plant in July and August 2018.

A dose of Washington comes to CPhI in Chicago

(Article)

CPhI N. America's keynote speaker explains what bipartisan bickering means for pharma

Modernizing manufacturing through a connected shop floor

(Article)

Eliminating siloed systems in favor of streamlined applications allows for greater agility and stronger collaboration, enabling pharma to meet the new quality management demands

Joint ventures in pharma (and nature)

(Article)

Shared pursuits might lead to bigger rewards

Sort By Relevance Sort By Date
1... 2 3 4 5 6 ...438